Aspartic acid functions as carbonyl trapper to inhibit the formation of advanced glycation end products by chemical chaperone activity.
Advanced glycation end products (AGEs) were implicated in pathology of numerous diseases. In this study, we present the bioactivity of aspartic acid (Asp) to inhibit the AGEs. Hemoglobin and bovine serum albumin (BSA) were glycated with glucose, fructose, and ribose in the presence and absence of Asp (100-200 μM). HbA1c inhibition was investigated using human blood and characterized by micro-column ion exchange chromatography. The effect of methyl glyoxal (MG) on hemoglobin and BSA was evaluated by fluorescence spectroscopy and gel electrophoresis. The effect of MG on red blood cells morphology was characterized by scanning electron micrographs. Molecular docking was performed on BSA with Asp. Asp is capable of inhibiting the formation of fluorescent AGEs by reacting with the reducing sugars. The presence of Asp as supplement in whole blood reduced the HbA1c% from 8.8 to 6.1. The presence of MG showed an increase in fluorescence and the presence of Asp inhibited the glycation thereby the fluorescence was quenched. MG also affected the electrophoretic mobility of hemoglobin and BSA by forming high molecular weight aggregates. Normal RBCs showed typical biconcave shape. MG modified RBCs showed twisted and elongated shape whereas the presence of ASP tends to protect RBC from twisting. Asp interacted with arginine residues of bovine serum albumin particularly ARG 194, ARG 198, and ARG 217 thereby stabilized the protein complex. We conclude that Asp has dual functions as a chemical chaperone to stabilize protein and as a dicarbonyl trapper, and thereby it can prevent the complications caused by glycation.
a Molecular Biophysics Laboratory, School of Chemical and Biotechnology , SASTRA University , Thanjavur 613401 , India.
Govindarajan
G
Prasanna
a Molecular Biophysics Laboratory, School of Chemical and Biotechnology , SASTRA University , Thanjavur 613401 , India.
N T
NT
Saraswathi
D000818:Animals; D001224:Aspartic Acid / Q000737:chemistry* / Q000494:pharmacology*; D002417:Cattle; D004912:Erythrocytes / Q000378:metabolism / Q000473:pathology / Q000648:ultrastructure; D006442:Glycated Hemoglobin / Q000037:antagonists & inhibitors; D017127:Glycation End Products, Advanced / Q000737:chemistry* / Q000378:metabolism; D006031:Glycosylation / Q000187:drug effects; D006454:Hemoglobins / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D006860:Hydrogen Bonding; D008958:Models, Molecular; D008968:Molecular Conformation; D062105:Molecular Docking Simulation; D012710:Serum Albumin, Bovine / Q000737:chemistry / Q000378:metabolism
D001224:Aspartic Acid; D006442:Glycated Hemoglobin; D017127:Glycation End Products, Advanced; D006454:Hemoglobins; D012710:Serum Albumin, Bovine
HbA1c; advanced glycation end products; aspartic acid; chemical chaperone; docking